BioSight
Companies
MoonLake Immunotherapeutics logo

MLTX

NASDAQZUG, V8
MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage immunotherapy company developing Sonelokimab, a tri-specific Nanobody licensed from Merck KGaA for the treatment of inflammatory and immune-mediated diseases. The company is focused on advancing SLK through regulatory submissions and commercialization, though it has not yet obtained approval for any products and expects to incur significant losses in the foreseeable future.

Price history not yet available for MLTX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar